CFO - ... And if history serves as a guide as you've looked over the last six months for instance, in the first quarter, as you know, we repurchased $275 million in shares. We've repurchased $225 million in shares in the second quarter, and we've been buying throughout the last two quarters and our share price is kind of in the range that it was this morning. So certainly that is an indication of how we're thinking about share repurchases. ...
He attacked for over a year. The question is, did he hold his short, or did he move in and out.
I hope he held and lost his shirt, but I am afraid that he didn't really believe his own BS.
Mallinckrodt had it's price target increased by analysts at JPMorgan Chase & Co. from $85.00 to $100.00 in a research report issued on Wednesday
Mallinckrodt had its price objective lifted by Piper Jaffray from $97.00 to $102.00 in a research note issued on Tuesday,
Mallinckrodt was Reiterated by Mizuho to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 80 from a previous price target of $78 . Mizuho advised their investors in a research report released on May 4, 2016.
Wells Fargo analyst David Maris reiterated a Buy rating on Mallinckrodt today.
Benzinga, Yahoo isn't cooperating.
The note says Mallinckrodt presented data from a study in 38 patients with persistently active systemic lupus erythematosus (SLE). Though the study did not meet its primary endpoint, Acthar was significantly better than placebo on a number of secondary endpoints. The primary endpoint was complete resolution of skin or joint activity per the Hybrid SLE Disease Activity Index at four weeks.
"Our featured speaker suggested that this primary endpoint set a very high bar for success, and further suggested that a range of other endpoints are just as important in assessing an efficacy signal," Amsellam wrote in a note.
The analyst said that rheumatologist also suggested that response durability (at least through 24-weeks) could drive even further usage in SLE.
"We continue to believe that visibility on sustained volume growth for Acthar is strong. Given that backdrop, along with high barriers to Acthar competition in our view and favorable dynamics for the hospital segment, we believe MNK is well-positioned to deliver a long-term EPS CAGR potentially in the low double-digits," Amsellam highlighted.
Piper Jaffray reiterated its Overweight rating and $97 target price on MNK after a Rheumatologist gave favorable view on Acthar for the treatment of Lupus.
According to a note from analyst David Amsellem, the rheumatologist noted that the results from a placebo (PBO)-controlled study that Mallinckrodt presented last November is driving him to use Acthar more in his lupus patients, and not necessarily just as a last resort treatment.
A Flight Ops Challenge – And the case for E-Taxi documented
March 31, 2016
E-taxi pioneers Wheeltug just released resarch (Pushback Time Savings summary 30 Mar 2016) it undertook monitoring airport operations. The case for adding e-taxi capabilities to aircraft has tended to focus on saving fuel burn. But fuel burn is no longer such an important issue in cost terms, though in “green” terms cutting fuel burn is still attractive. Wheeltug has, for some time now, been focusing on time savings rather than fuel savings. A generally accepted cost for airline operations is $100 per minute. More on this shortly.
Wheeltug estimates that by deploying e-taxi, an airline could save approximately a total of seven minutes per aircraft per gate push-back. ...
... Airlines that deploy e-taxi could see big time savings that could mean getting another flight out each aircraft every other day or simply serious financial benefits – taking 30 minutes as a guide, this is worth $3,000 per day per plane. Improved operational efficiencies are significant.
And that ignores the other benefits from things like quieter airports and less air pollution. It appears a lot of tangible benefits could come from deploying a technology like e-taxi.
(Seems high to me, but even a fraction would be a major cost savings)
Bloomberg - "Mallinckrodt is working with advisers to seek potential buyers for its nuclear imaging division, according to people familiar with the matter.
The business could fetch about $800 million to $1 billion and is attracting interest from private equity firms, "
(APD371) " we expect to share top line results AROUND the end of March. "
"Oct 5, 2015 - Arena Pharmaceuticals said Monday that its president and CEO, Jack Lief, has left ... "
It hasn't been 7 months.
"Andrew Left of Citron Research, the short seller whose October report sent Valeant Pharmaceuticals tumbling and sparked an SEC investigation into the company, says he's not shorting the stock.
Not because he thinks Valeant's problems are over, but because the company is "uninvestable."
In other words, he isn't willing to touch it, even if it is to short the stock. "